Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
$0.66
$1.11
$0.62
▼
$8.81
$13.39M0.4938,601 shs10,975 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.44
$3.36
$1.03
▼
$8.48
$16.10M1.7421,598 shs15,705 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.65
+0.6%		$0.82
$0.63
▼
$2.79
$3.98M568,922 shs12,350 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.00
$4.20
$1.11
▼
$19.65
$16.61M0.13,207 shs26 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
0.00%-19.41%-39.84%-55.28%+66,179,900.00%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%-1.71%+0.29%+5.52%+34.11%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00%+3.27%-19.48%-39.72%-45.50%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-20.00%-20.00%+5.26%-59.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
$0.66
$1.11
$0.62
▼
$8.81
$13.39M0.4938,601 shs10,975 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.44
$3.36
$1.03
▼
$8.48
$16.10M1.7421,598 shs15,705 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.65
+0.6%		$0.82
$0.63
▼
$2.79
$3.98M568,922 shs12,350 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.00
$4.20
$1.11
▼
$19.65
$16.61M0.13,207 shs26 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
0.00%-19.41%-39.84%-55.28%+66,179,900.00%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%-1.71%+0.29%+5.52%+34.11%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00%+3.27%-19.48%-39.72%-45.50%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-20.00%-20.00%+5.26%-59.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
1.00
SellN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
1.00
SellN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RDHL, AIXC, ZIVO, and CYCN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/21/2026
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/6/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
N/AN/AN/AN/A($0.75) per shareN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$1.99M8.08N/AN/A$2.31 per share1.49
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K13.71N/AN/A$0.83 per share0.79
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,047.82N/AN/A($0.81) per share-4.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
-$16.97M-$6.47N/AN/AN/AN/A-771.52%-79.52%N/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430K$900.000.00N/AN/AN/AN/AN/A8/20/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)

Latest RDHL, AIXC, ZIVO, and CYCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2026H1 2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$435.00N/AN/AN/A$22.70 millionN/A
8/4/2026N/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$7.10N/AN/AN/A$1.50 millionN/A
5/12/2026Q1 2026
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
N/A-$0.79N/A-$0.79N/AN/A
5/12/2026Q1 2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
N/A
11.57
11.57
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
1.80
1.80
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
0.34
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
3.18%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
1.17%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Qualigen Therapeutics, Inc. stock logo
AIXC
Qualigen Therapeutics
5020.24 million20.00 millionN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
304.68 million3.08 millionNo Data
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2106.08 million5.67 millionNo Data
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.15 million2.91 millionNot Optionable

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Below 200-Day Moving Average - Here's Why
July 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30927836
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Harmony Biosciences Holdings
March 4, 2024  |  forbes.comhttps://www.forbes.com/companies/harmony-biosciences-holdings/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:AIXC

$0.66 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.66 +0.00 (+0.03%)
As of 07/31/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.44 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$3.40 -0.04 (-1.02%)
As of 07/31/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.65 +0.00 (+0.62%)
Closing price 07/31/2026 03:57 PM Eastern
Extended Trading
$0.66 +0.00 (+0.15%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$4.00 0.00 (0.00%)
As of 07/31/2026

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas